The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1589
January 13, 2020
View Complete Issue         Table of Contents 2019 
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
January 13, 2020 (Issue: 1589)
The FDA has approved Trikafta (Vertex), a fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor, tezacaftor, and ivacaftor, for oral treatment of cystic fibrosis (CF) in patients ≥12...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
Article code: 1589b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.